Cargando…
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas. Rapamycin-derivates as allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclinical and clinical anti-lymphoma activity. Here, we asse...
Autores principales: | Tarantelli, Chiara, Gaudio, Eugenio, Hillmann, Petra, Spriano, Filippo, Sartori, Giulio, Aresu, Luca, Cascione, Luciano, Rageot, Denise, Kwee, Ivo, Beaufils, Florent, Zucca, Emanuele, Stathis, Anastasios, Wymann, Matthias P., Cmiljanovic, Vladimir, Fabbro, Doriano, Bertoni, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627883/ https://www.ncbi.nlm.nih.gov/pubmed/31167506 http://dx.doi.org/10.3390/cancers11060775 |
Ejemplares similares
-
Preclinical Development of PQR514, a Highly Potent
PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety
por: Borsari, Chiara, et al.
Publicado: (2019) -
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma
por: Spriano, Filippo, et al.
Publicado: (2022) -
Exon–Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation
por: Munz, Nicolas, et al.
Publicado: (2021) -
The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620
por: Zha, Jian-hua, et al.
Publicado: (2021) -
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention
por: Bohnacker, Thomas, et al.
Publicado: (2017)